

Jun Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/53926/publications.pdf>

Version: 2024-02-01

61
papers

1,959
citations

394286

19
h-index

289141

40
g-index

70
all docs

70
docs citations

70
times ranked

2513
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). <i>Liver Cancer</i> , 2020, 9, 682-720.	4.2	427
2	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , 2018, 7, 235-260.	4.2	426
3	<i>TERT</i> Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 258-265.	2.8	92
4	A comprehensive genome-wide analysis of long noncoding RNA expression profile in hepatocellular carcinoma. <i>Cancer Medicine</i> , 2017, 6, 2932-2941.	1.3	84
5	Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study. <i>Oncologist</i> , 2014, 19, 1169-1178.	1.9	71
6	Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy. <i>Endocrinology and Metabolism</i> , 2019, 34, 215.	1.3	68
7	Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. <i>Oncotarget</i> , 2017, 8, 42252-42261.	0.8	54
8	BRAFV600E Mutation Associated With Non- ¹³¹ I Radioiodine-Avid Status in Distant Metastatic Papillary Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 2014, 39, 675-679.	0.7	52
9	Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine- ¹³¹ I-Refractory Differentiated Thyroid Cancer. <i>JAMA Oncology</i> , 2022, 8, 242.	3.4	50
10	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 57-57.	0.4	46
11	CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. <i>Molecular Cancer</i> , 2022, 21, 11.	7.9	46
12	Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1307-1313.	1.8	36
13	Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 29.	0.6	32
14	Comprehensive molecular characterization of inhibitors of apoptosis proteins (IAPs) for therapeutic targeting in cancer. <i>BMC Medical Genomics</i> , 2020, 13, 7.	0.7	32
15	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). <i>Annals of Translational Medicine</i> , 2015, 3, 322.	0.7	32
16	Upregulated microRNA-429 inhibits the migration of HCC cells by targeting TRAF6 through the NF- κ B pathway. <i>Oncology Reports</i> , 2017, 37, 2883-2890.	1.2	30
17	The effect of a coix seed oil injection on cancer pain relief. <i>Supportive Care in Cancer</i> , 2019, 27, 461-465.	1.0	30
18	Identification of stage-specific biomarkers in lung adenocarcinoma based on RNA-seq data. <i>Tumor Biology</i> , 2015, 36, 6391-6399.	0.8	23

#	ARTICLE	IF	CITATIONS
19	Richer fusion network for breast cancer classification based on multimodal data. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 134.	1.5	22
20	MicroRNA-199a-3p inhibits tumorigenesis of hepatocellular carcinoma cells by targeting ZHX1/PUMA signal. <i>American Journal of Translational Research (discontinued)</i> , 2017, 9, 2457-2465.	0.0	21
21	Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors. <i>Thoracic Cancer</i> , 2018, 9, 542-547.	0.8	20
22	NF κ B mediated elevation of KCNJ11 promotes tumor progression of hepatocellular carcinoma through interaction of lactate dehydrogenase A. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 246-253.	1.0	19
23	Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1034-1039.	3.3	18
24	Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3027-e3036.	1.8	15
25	Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients With Typical Lung Carcinoid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 607-614.	0.6	14
26	Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2012, 24, 291-298.	0.7	13
27	Chinese guidelines on the management of renal cell carcinoma (2015 edition). <i>Annals of Translational Medicine</i> , 2015, 3, 279.	0.7	13
28	Pharmacovigilance Bibliometrics: Visualizing Thematic Development in the Category of Pharmacology and Pharmacy in Web of Science. <i>Frontiers in Pharmacology</i> , 2021, 12, 731757.	1.6	13
29	miR-142 suppresses proliferation and induces apoptosis of osteosarcoma cells by upregulating Rb. <i>Oncology Letters</i> , 2018, 16, 733-740.	0.8	12
30	A comparative analysis of infection in patients with malignant cancer: A clinical pharmacist consultation study. <i>Journal of Infection and Public Health</i> , 2019, 12, 789-793.	1.9	11
31	Serum thyrotropin level of 30 \pm 4IU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer. <i>Endocrine</i> , 2016, 53, 166-173.	1.1	9
32	Cytoplasmic expression of estrogen receptor β may predict poor outcome of EGFR-TKI therapy in metastatic lung adenocarcinoma. <i>Oncology Letters</i> , 2018, 16, 2382-2390.	0.8	8
33	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 <sc>CONCUR</sc> trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1307-1316.	1.4	8
34	Chinese guidelines on the management of renal cell carcinoma (2015 edition). <i>Chinese Clinical Oncology</i> , 2016, 5, 12.	0.4	8
35	Suppressed thyroglobulin performs better than stimulated thyroglobulin in defining an excellent response in patients with differentiated thyroid cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 247-251.	0.5	7
36	Differential regulation of AKT1 contributes to survival and proliferation in hepatocellular carcinoma cells by mediating Notch1 expression. <i>Oncology Letters</i> , 2018, 15, 6857-6864.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1469-1488.	0.8	7
38	A multicenter, single arm phase II trial of a small molecule immune-modulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4077-4077.	0.8	7
39	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
40	Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 809068.	1.3	7
41	Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 4701-4709.	0.8	6
42	Clinical Characteristics and Prognosis of Gastrointestinal Metastases in Solid Tumor Patients: A Retrospective Study and Review of Literatures. <i>Analytical Cellular Pathology</i> , 2019, 2019, 1-7.	0.7	6
43	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 646-651.	0.8	4
44	Establishment and validation of a novel droplet digital PCR assay for ultrasensitive detection and dynamic monitoring of EGFR mutations in peripheral blood samples of non-small-cell lung cancer patients. <i>Clinica Chimica Acta</i> , 2020, 510, 88-96.	0.5	4
45	Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 4169-4180.	0.9	4
46	Clinical characteristics of hepatocellular carcinoma patients with normal serum alpha-fetoprotein level: A study of 112 consecutive cases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e336-e340.	0.7	3
47	Common and distinct features of potentially predictive biomarkers in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung by systematic and integrated analysis. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1126.	0.6	3
48	Deployment and integration of a cognitive technology in China: Experiences and lessons learned.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6538-6538.	0.8	3
49	Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb. <i>Oncotarget</i> , 2017, 8, 97407-97415.	0.8	3
50	Safety and tolerability profile of raltitrexed in Chinese patients with locally advanced or recurrent and metastatic colorectal cancer: A phase IV trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 571-571.	0.8	3
51	Prognostic nomograms for patients undergoing radical operation for stage I-III appendiceal adenocarcinoma: A surveillance, epidemiology, and end results database analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 1656.	0.3	3
52	Reasons for discordance in treatment approaches between oncology practice and clinical decision support in China.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6555-6555.	0.8	2
53	Employing an oncology decision-support system to quantify treatment variation.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18067-e18067.	0.8	2
54	Decreased expression of ARID1A invasively downregulates the expression of ribosomal proteins in hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2021, 15, 497-508.	0.6	1

#	ARTICLE	IF	CITATIONS
55	Impact of decision-support system and guideline treatment concordance on response rate in advanced lung cancer.. Journal of Clinical Oncology, 2019, 37, e20006-e20006.	0.8	1
56	Apatinib versus placebo in patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: Post hoc analyses from the REALITY randomized clinical trial.. Journal of Clinical Oncology, 2022, 40, 6095-6095.	0.8	1
57	In vitro anti-irradiation effects of a polypeptide from Chlamys farreri. Chinese Journal of Clinical Oncology, 2005, 2, 473-479.	0.0	0
58	Polymorphisms of ERCC1, XPD, XRCC1 and XPG predict clinical outcome in advanced gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Clinical Oncology and Cancer Research, 2009, 6, 328-336.	0.1	0
59	Abstract 2739: ARID1A deficiency in HBV related hepatocarcinoma patients is associated with upregulated immune activity. , 2021, , .		0
60	CDK6 inhibits lymphoid cell infiltration and represents a prognostic marker in HPV+ squamous cell carcinoma of head and neck. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 901-909.	0.7	0
61	Preliminary results of raltitrexed in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, real-world study.. Journal of Clinical Oncology, 2022, 40, 3591-3591.	0.8	0